tradingkey.logo

LENSAR Inc

LNSR
View Detailed Chart

12.380USD

-0.020-0.16%
Close 09/19, 16:00ETQuotes delayed by 15 min
147.73MMarket Cap
LossP/E TTM

LENSAR Inc

12.380

-0.020-0.16%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.16%

5 Days

-0.72%

1 Month

-0.96%

6 Months

-26.62%

Year to Date

+38.48%

1 Year

+187.24%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
87 / 207
Overall Ranking
194 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Hold
Current Rating
15.000
Target Price
+20.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 51.29% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 53.49M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 57.70.
Fairly Valued
The company’s latest PE is -2.95, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.77M shares, increasing 4.23% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 563.58K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.07.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
Ticker SymbolLNSR
CompanyLENSAR Inc
CEOMr. Nicholas T. (Nick) Curtis
Websitehttps://www.lensar.com/
KeyAI